Take another look.

Carboplatin/paclitaxel is the standard chemo to use concurrently with radiation for locally advanced non-small cell lung cancer (NSCLC). So it’s got to be the best, right? You may have missed last year’s randomized trial demonstrating a significant overall survival advantage at three years with concurrent with etoposide/cisplatin, instead, not to mention lower rates of pneumonitis. Don't feel bad, all the guidelines missed it, too.